Tag : GW Pharma

Current News Hemp News Market Watch

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®. The clinical results have shown that their product has significantly helped patients with Dravet syndrome treat and reduce their seizures associated with the...
Global Health Hemp News Market Watch

GW Pharma to Raise $300M Via Public Offering

Editor
GW Pharmaceuticals plc (NASDAQ: GWPH) announced this morning that the company’s wholly owned subsidiary, Greenwich Biosciences, plans to raise $300 million dollars via the selling GW Pharma’s common shares on the NASDAQ Global Market. The company is planning to offer the underwriters an additional 30-day option to purchase an additional $45...
Current News Health

GW Pharma’s New Compound GWP42006 Fails Initial Trial Testing

Editor
On February 21, 2018 GW Pharmaceuticals PLC (Nasdaq:GWPH) (“GW,”) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint.  The trial was conducted outside the United States, primarily in Eastern Europe.  In the trial’s...